Hansa Biopharma Raises $24.3M in Directed Cash Share Issue, Restructures Debt, and Reports Q2 2025 Financial Results

Hansa Biopharma reported Q2 2025 financial results, including a 76% increase in IDEFIRIX product sales compared to the previous year. The company secured a directed cash share issue of approximately $24.3M and restructured its NovaQuest debt. With a cash runway extending into Q2 2026, Hansa plans to focus on near-term catalysts, strategic pipeline decisions, and commercializing IDEFIRIX in Europe. Two Phase 3 trial readouts are expected in the second half of 2025.

Hansa Biopharma AB (Nasdaq Stockholm: HNSA) has reported its interim financial results for the period January-June 2025, highlighting a significant increase in IDEFIRIX product sales and successful debt restructuring. The company's Q2 2025 IDEFIRIX sales surged by 76% compared to the same period last year, reaching 47.8 MSEK. This growth is attributed to strong commercial performance and increased demand for the company's innovative treatments.

In a strategic move to bolster its financial position, Hansa secured a directed cash share issue of approximately 232 MSEK (US $24.3M) and restructured its debt agreement with NovaQuest. The company offset US $14.9M of outstanding debt through the issuance of new shares, with the remaining debt to be paid in fixed cash installments in 2027, 2028, and 2029. Additionally, a true-up payment of approximately US $14.9M is due on January 31, 2026, which can be settled in cash or equity at the company's discretion.

The successful capital raise will support two pivotal Phase 3 trials scheduled for the second half of 2025. These include the ConfIdeS US pivotal trial in kidney transplantation and the GOOD-IDES-02 trial in anti-GBM. The company's cash runway has been extended to Q2 2026, allowing it to focus on near-term catalysts, strategic pipeline decisions, and the continued commercialization of IDEFIX in Europe.

Hansa's financial summary for the period indicates a revenue of 49.1 MSEK, with product sales accounting for 47.8 MSEK. SG&A expenses and R&D expenses totaled 90.5 MSEK and 95.8 MSEK, respectively. The company reported a loss from operations of 154.8 MSEK and a net cash used in operations of 111.7 MSEK. Cash and short-term investments stood at 354.4 MSEK.

The company remains on track to report data from the 20-HMedIdeS-17 study (ConfIdeS) and expects a Biologics License Application (BLA) submission to the U.S. FDA in the second half of 2025. Positive data from the 15-HMedIdeS-09 Phase 2 trial was presented at the Peripheral Nerve Society (PNS) annual meeting in May. Enrollment is ongoing in the GNT-018-IDES Phase 2 trial in Crigler Najjar, and the Phase 1b trial SRP-9001-104 with Sarepta is on track for an initial data readout later this year.

Hansa Biopharma will host a telephone conference today, Thursday, July 17, 2025, at 14:00 CEST / 8:00 am EDT, to discuss the interim results and provide a business and pipeline update. The event will be hosted by Renée Aguiar-Lucander, CEO, Evan Ballantyne, CFO, Hitto Kaufmann, CSTO, and Maria Törnsén, COO and President U.S.

References:
[1] https://www.prnewswire.com/news-releases/hansa-biopharma-reports-second-quarter-and-interim-january-june-2025-financial-results-302507679.html
[2] https://www.tradingview.com/news/reuters.com,2025-07-17:newsml_Wkr3VKJdC:0-hansa-biopharma-reports-second-quarter-and-interim-january-june-2025-financial-results/